KRAS Mutation Detection

KRAS mutations have been implicated in the pathogenesis of different cancers, particularly common in colorectal cancer, lung cancer, melanoma, and pancreatic cancer (1,2). Analysis of KRAS mutations, particularly in codons 12, 13 and 61, has been shown to be incredibly valuable in optimizing the anti-EGFR therapies for different type of cancers like metastatic colorectal cancers (3-5).

Trimgen’s MutectorTM reagents
Based on Shifted Termination Assay (STA) technology, the kit uses special chemistry and a modified enzyme mixture to enrich the mutation signal and detect low level mutations in the sample.  The STA technology has been widely used to detect BRAF, KRAS and other mutations in clinical samples including FFPE samples  (see STA/Mutector-related Publications).

The difference:

  • Detect more mutations - 17 mutations including the rare mutations (see below)    
  • Use of small clinical samples - such as fine needle aspiration (FNA)
  • Simultaneously detect all possible mutations in target codon
  • Sequencing-like accuracy and PCR-like sensitivity  

Assay Information

Target Mutations      Codon 12: G12AG12CG12DG12RG12SG12V
                                  Codon 13: G13AG13CG13DG13RG13SG13V
                                  Codon 61: Q61EQ61H (CAT), Q61H*(CAC), Q61LQ61R

Assay Platform        Capillary sequencer ABI 3100, 3700, 3130, 3500
Assay Sensitivity     Detects 1-2% KRAS mutations
Sample required      20-160 ng DNA 

Assay Workflow

Order Information

Cat. No. Product NameTarget Mutations SizeDocuments
GP05-C3KRAS mutation detection kit12 KRAS mutations in codon 12 & 13 32 rxnManualProduct flyer
GP06KRAS codon 61 detection kit5 KRAS mutations in codon 6132 rxnManualProduct flyer

For research use only. Not for use in diagnostic procedures.

Simultaneously detect all mutations of codon 12 in one tube:

Test results from FFPE samples:


Simultaneously detect all mutations of codon 13 in one tube:

Test results from FFPE samples:


Simultaneously detect 5 mutations of codon 61 (kit controls) in one tube:

Test result from FFPE samples:

Related Products


  1. Schubbert S et al. (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 4:295.
  2. Fernández-Medarde A et al. (2011). Ras in cancer and developmental diseases. Genes Cancer. 2:344.
  3. F Di Fiore, R et al. (2009). Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer.  103: 1765.
  4. De Roock W et al. (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594.
  5. Imamura Y et al. (2014). Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 13:135.